Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mandy Jackson
Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.
Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.
Women in leadership roles has become a much discussed issue for the biopharma industry, but less attention seems to be focused on racial diversity. Scrip's panel talks about challenges and opportunities, and offers advice for next generation employees.